In Vitro Activity of Imipenem-Relebactam and Ceftolozane-Tazobactam against Resistant Gram-Negative Bacilli | Zendy

Suzannah M. Schmidt-Malan | Zendy; Avisya J. Mishra | Zendy; Ammara Mushtaq | Zendy; Cassandra L. Brinkman | Zendy; Robin Patel | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In Vitro Activity of Imipenem-Relebactam and Ceftolozane-Tazobactam against Resistant Gram-Negative Bacilli

Author(s) -

Suzannah M. Schmidt-Malan,

Avisya J. Mishra,

Ammara Mushtaq,

Cassandra L. Brinkman,

Robin Patel

Publication year - 2018

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00533-18

Subject(s) - ertapenem , bacilli , meropenem , cefepime , microbiology and biotechnology , imipenem , antimicrobial , tazobactam , biology , beta lactamase inhibitors , ceftriaxone , medicine , antibiotics , antibiotic resistance , bacteria , genetics

Understanding which antimicrobial agents are likely to be active against Gram-negative bacilli can guide selection of antimicrobials for empirical therapy as mechanistic rapid diagnostics are adopted. In this study, we determined the MICs of a novel β-lactam–β-lactamase inhibitor combination, imipenem-relebactam, along with ceftolozane-tazobactam, imipenem, ertapenem, meropenem, ceftriaxone, and cefepime, against 282 drug-resistant isolates of Gram-negative bacilli.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research